- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Kristie L. Kahl | Authors
Dostarlimab Improves Antitumor Activity in Advanced Endometrial Cancer
June 09, 2022
The GARNET trial expansion cohorts showed durable antitumor activity across multiple populations of patients treated with dostarlimab in advanced endometrial cancer.
Cobimetinib Plus Vemurafenib Produces Antitumor Activity in Patients With BRAF Mutations
June 07, 2022
Results from a cohort of the TAPUR study showed that the combination of cobimetinib plus vemurafenib demonstrated antitumor activity among patients with BRAF mutations who are not otherwise eligible for treatment with other FDA-approved therapies.
Adagrasib Induces Promising Efficacy, Deep Responses in KRAS G12C NSCLC
June 03, 2022
The KRAS G12C inhibitor adagrasib demonstrated an objective response rate of 43% and disease control rate of 80% among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.
Addition of Nimotuzumab to Chemotherapy Increases OS in KRAS Wild-Type Advanced Pancreatic Cancer
June 03, 2022
Nimotuzumab plus gemcitabine improved overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct.
Oncolytic Adenovirus, CG0070, Plus Pembrolizumab Shows Promise in BCG-Unresponsive NMIBC
April 13, 2022
The addition of an immune checkpoint inhibitor to CG0070 induced a complete response rate of 88.9% among 18 patients in the phase 2 CORE1 trial.
Genetically-Adjusted PSA May Be a More Accurate vs PSA Alone as Prostate Cancer Screening Biomarker
April 11, 2022
Genetic determinants of PSA proved to robustly predict prostate cancer diagnoses and improve the detection of aggressive disease; however, larger and more diverse studies are still required.
Adding Ibrutinib to FCR Combo Shows Promise as Time-Limited Therapy in Younger Patients With CLL
December 14, 2021
The time-limited combination of ibrutinib plus chemoimmunotherapy in younger fit patients with chronic lymphocytic leukemia increased the rate of complete responses with bone marrow undetectable minimal residual disease, regardless of IGHV mutation, according to long-term follow-up data.
MRD-Adapted Therapy Approach May Allow for Treatment-Free Surveillance in Certain Patients With Newly Diagnose Myeloma
December 12, 2021
Among patients with newly diagnosed multiple myeloma, 80% of a study cohort reached MRD negativity following treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone.
Adding Eryaspase to Chemotherapy Shows Promise in Patients with ALL at Risk for Hypersensitivity Reactions
December 12, 2021
The infusion of E-Coli- and Erwinia-derived asparaginase therapies combined with chemotherapy appeared to be well tolerated with biological efficacy in patients with acute lymphoblastic leukemia under the age of 55, providing an additional option for patients for whom further asparagine treatment is contraindicated due to toxicity.
Addition of Ibrutinib to R-Mini-Chop for Newly Diagnosed DLBCL Shows Promise in an Elderly Population
December 12, 2021
Data presented at 2021 ASH indicate that 2-year progression-free survival rates were improved when ibrutinib was added to rituximab plus mini-CHOP in an elderly cohort of patients with previously untreated diffuse large B-cell lymphoma.